{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T16:41:14Z","timestamp":1751474474424,"version":"3.37.3"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"publisher","award":["E81I18000330005"],"award-info":[{"award-number":["E81I18000330005"]}],"id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Prin-E85F22000060006"],"award-info":[{"award-number":["Prin-E85F22000060006"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004271","name":"Sapienza Universit\u00e0 di Roma","doi-asserted-by":"publisher","award":["#RM11916B74788236"],"award-info":[{"award-number":["#RM11916B74788236"]}],"id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant mesothelioma (MM) is a rare orphan aggressive neoplasia with low survival rates. Among the other signaling pathways, ErbB receptors and Hh signaling are deregulated in MM. Thus, molecules involved in these signaling pathways could be used for targeted therapy approaches. The aim of this study was to evaluate the effects of inhibitors of Hh- (GANT-61) and ErbB receptors (Afatinib)-mediated signaling pathways, when used alone or in combination, on growth, cell cycle, cell death and autophagy, modulation of molecules involved in transduction pathways, in three human MM cell lines of different histotypes. The efficacy of the combined treatment was also evaluated in a murine epithelioid MM cell line both in vitro and in vivo. This study demonstrated that combined treatment with two inhibitors counteracting the activation of two different signaling pathways involved in neoplastic transformation and progression, such as those activated by ErbB and Hh signaling, is more effective than the single treatments in reducing MM growth in vitro and in vivo<jats:italic>.<\/jats:italic>This study may have clinical implications for the development of targeted therapy approaches for MM.<\/jats:p>","DOI":"10.1186\/s12967-022-03490-9","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T13:03:46Z","timestamp":1656162226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-8896","authenticated-orcid":false,"given":"Roberto","family":"Bei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Benvenuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Focaccetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Fazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Nardozi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Angiolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ciuffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Cifaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Carrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martino Tony","family":"Miele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Bei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Barillari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Manzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"De Smaele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Modesti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Masuelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"3490_CR1","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","volume":"9","author":"SG Gray","year":"2020","unstructured":"Gray SG, Mutti L. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl Lung Cancer Res. 2020;9:S100\u201319.","journal-title":"Transl Lung Cancer Res"},{"key":"3490_CR2","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.21037\/tlcr.2020.01.16","volume":"9","author":"MJ Disselhorst","year":"2020","unstructured":"Disselhorst MJ, Baas P. Chemotherapy options versus \u201cNovel\u201d therapies: how should we treat patients with malignant pleural mesothelioma. Transl Lung Cancer Res. 2020;9:S77\u201385.","journal-title":"Transl Lung Cancer Res"},{"key":"3490_CR3","first-page":"2484","volume":"7","author":"A Del Gobbo","year":"2014","unstructured":"Del Gobbo A, Fiori S, Gaudioso G, Bonaparte E, Tabano S, Palleschi A, Bosari S, Ferrero S. Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature. Int J Clin Exp Pathol. 2014;7:2484\u20139.","journal-title":"Int J Clin Exp Pathol"},{"key":"3490_CR4","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"3490_CR5","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-Label, Phase 3 Trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet"},{"key":"3490_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1245\/ASO.2006.05.041","volume":"13","author":"C Brigand","year":"2006","unstructured":"Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405\u201312.","journal-title":"Ann Surg Oncol"},{"key":"3490_CR7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/000313480106701019","volume":"67","author":"B Loggie","year":"2001","unstructured":"Loggie B, Fleming R, McQuellon R, Russell G, Geisinger K, Levine E. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67:999\u20131003.","journal-title":"Am Surg"},{"key":"3490_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.tips.2011.03.011","volume":"32","author":"RE Favoni","year":"2011","unstructured":"Favoni RE, Florio T. Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma. Trends Pharmacol Sci. 2011;32:463\u201379.","journal-title":"Trends Pharmacol Sci"},{"key":"3490_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"3490_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M, Pass HI. Whole-exome sequencing reveals frequent genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75:264\u20139.","journal-title":"Cancer Res"},{"key":"3490_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","volume":"10","author":"M Lo Iacono","year":"2015","unstructured":"Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S, Bironzo P, Novello S, Musmeci L, Volante M, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol. 2015;10:492\u20139.","journal-title":"J Thorac Oncol"},{"key":"3490_CR12","first-page":"2331","volume":"36","author":"G Ugurluer","year":"2016","unstructured":"Ugurluer G, Chang K, Gamez ME, Arnett AL, Jayakrishnan R, Miller RC, Sio TT. Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma. Anticancer Res. 2016;36:2331\u20138.","journal-title":"Anticancer Res"},{"key":"3490_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.2174\/1389450116666150804110714","volume":"17","author":"S Thellung","year":"2016","unstructured":"Thellung S, Favoni R, W\u00fcrth R, Nizzari M, Pattarozzi A, Daga A, Florio T, Barbieri F. Molecular pharmacology of malignant pleural mesothelioma: challenges and perspectives from preclinical and clinical studies. Curr Drug Targets. 2016;17:824\u201349.","journal-title":"Curr Drug Targets"},{"key":"3490_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2174\/092986708783955446","volume":"15","author":"C Palumbo","year":"2008","unstructured":"Palumbo C, Bei R, Procopio A, Modesti A. Molecular targets and targeted therapies for malignant mesothelioma. Curr Med Chem. 2008;15:855\u201367.","journal-title":"Curr Med Chem"},{"key":"3490_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fonc.2020.00343","volume":"10","author":"L Cantini","year":"2020","unstructured":"Cantini L, Hassan R, Sterman DH, Aerts JGJV. Emerging treatments for malignant pleural mesothelioma: where are we heading? Front Oncol. 2020;10:343.","journal-title":"Front Oncol"},{"key":"3490_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","volume":"51","author":"A Destro","year":"2006","unstructured":"Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, et al. EGFR Overexpression in Malignant Pleural Mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 2006;51:207\u201315.","journal-title":"Lung Cancer"},{"key":"3490_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/17425247.2019.1598374","volume":"16","author":"PL Chia","year":"2019","unstructured":"Chia PL, Scott AM, John T. Epidermal Growth Factor Receptor (EGFR)-targeted therapies in mesothelioma. Expert Opin Drug Deliv. 2019;16:441\u201351.","journal-title":"Expert Opin Drug Deliv"},{"key":"3490_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","volume":"393","author":"A Klampatsa","year":"2017","unstructured":"Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, et al. Intracavitary \u2018T4 Immunotherapy\u2019 of Malignant Mesothelioma Using Pan-ErbB Re-Targeted CAR T-Cells. Cancer Lett. 2017;393:52\u20139.","journal-title":"Cancer Lett"},{"key":"3490_CR19","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.jtho.2017.04.028","volume":"12","author":"N Agatsuma","year":"2017","unstructured":"Agatsuma N, Yasuda Y, Ozasa H. Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR successfully treated with afatinib. J Thorac Oncol. 2017;12:e141\u20133.","journal-title":"J Thorac Oncol"},{"key":"3490_CR20","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","volume":"25","author":"LL Garland","year":"2007","unstructured":"Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJP, Testa JR, Altomare DA, Borden EC. Phase II Study of Erlotinib in Patients with Malignant Pleural Mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007;25:2406\u201313.","journal-title":"J Clin Oncol"},{"key":"3490_CR21","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","volume":"11","author":"R Govindan","year":"2005","unstructured":"Govindan R, Kratzke R, Herndon J, Niehans G, Vollmer R, Watson D, Green M, Kindler H, Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase ii study by the cancer and leukemia Group B. Clin Cancer Res. 2005;11:2300\u20134.","journal-title":"Clin Cancer Res"},{"key":"3490_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/PDM.0b013e3182a3645e","volume":"23","author":"V Schildgen","year":"2015","unstructured":"Schildgen V, Pabst O, Tillmann R, L\u00fcsebrink J, Schildgen O, Ludwig C, Brockmann M, Stoelben E. Low frequency of EGFR Mutations in Pleural Mesothelioma patients, Cologne Germany. Appl Immunohistochem Mol Morphol. 2015;23:118\u201325.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"3490_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/JTO.0b013e31819c8661","volume":"4","author":"V Velcheti","year":"2009","unstructured":"Velcheti V, Kasai Y, Viswanathan AK, Ritter J, Govindan R. Absence of mutations in the Epidermal Growth Factor Receptor (EGFR) kinase domain in patients with mesothelioma. J Thorac Oncol. 2009;4:559.","journal-title":"J Thorac Oncol"},{"key":"3490_CR24","first-page":"41","volume":"14","author":"FA Shepherd","year":"2016","unstructured":"Shepherd FA. Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, There Is a Role for EGFR TKIs in these patients. Clin Adv Hematol Oncol. 2016;14:41\u20134.","journal-title":"Clin Adv Hematol Oncol"},{"key":"3490_CR25","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.18632\/oncotarget.2941","volume":"6","author":"TT Chao","year":"2015","unstructured":"Chao TT, Wang CY, Chen YL, Lai CC, Chang FY, Tsai YT, Chao CHH, Shiau CW, Huang YCT, Yu CJ, et al. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget. 2015;6:2164\u201379.","journal-title":"Oncotarget"},{"key":"3490_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.devcel.2008.11.010","volume":"15","author":"J Jiang","year":"2008","unstructured":"Jiang J, Hui C. Hedgehog signaling in development and cancer. Dev Cell. 2008;15:801\u201312.","journal-title":"Dev Cell"},{"key":"3490_CR27","doi-asserted-by":"publisher","first-page":"9250","DOI":"10.18632\/oncotarget.7062","volume":"7","author":"M Benvenuto","year":"2016","unstructured":"Benvenuto M, Masuelli L, De Smaele E, Fantini M, Mattera R, Cucchi D, Bonanno E, Di Stefano E, Frajese GV, Orlandi A, et al. In Vitro and in Vivo inhibition of breast cancer cell growth by targeting the Hedgehog\/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) Inhibitors. Oncotarget. 2016;7:9250\u201370.","journal-title":"Oncotarget"},{"key":"3490_CR28","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1101\/gad.1693608","volume":"22","author":"M Varjosalo","year":"2008","unstructured":"Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008;22:2454\u201372.","journal-title":"Genes Dev"},{"key":"3490_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22031042","volume":"22","author":"S Iriana","year":"2021","unstructured":"Iriana S, Asha K, Repak M, Sharma-Walia N. Hedgehog signaling: implications in cancers and viral infections. Int J Mol Sci. 2021;22:1\u201330.","journal-title":"Int J Mol Sci"},{"key":"3490_CR30","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1158\/1078-0432.CCR-12-0599","volume":"18","author":"Y Shi","year":"2012","unstructured":"Shi Y, Moura U, Opitz I, Soltermann A, Rehrauer H, Thies S, Weder W, Stahel RA, Felley-Bosco E. Role of hedgehog signaling in malignant pleural mesothelioma. Clin Cancer Res. 2012;18:4646\u201356.","journal-title":"Clin Cancer Res"},{"key":"3490_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21186863","volume":"21","author":"KS Jeng","year":"2020","unstructured":"Jeng KS, Sheen IS, Leu CM, Tseng PH, Chang CF. The role of smoothened in cancer. Int J Mol Sci. 2020;21:1\u201320.","journal-title":"Int J Mol Sci"},{"key":"3490_CR32","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.2741\/4180","volume":"18","author":"M Benvenuto","year":"2013","unstructured":"Benvenuto M, Fantini M, Masuelli L, De Smaele E, Zazzeroni F, Tresoldi I, Calabrese G, Galvano F, Modesti A, Bei R. Inhibition of ErbB receptors, hedgehog and NF-KappaB signaling by polyphenols in cancer. Front Biosci (Landmark Ed). 2013;18:1290\u2013310.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3490_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-9966-32-7","volume":"32","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, Jablons DM, He B, Lui N. SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma. J Exp Clin Cancer Res. 2013;32:1\u20138.","journal-title":"J Exp Clin Cancer Res"},{"key":"3490_CR34","first-page":"381","volume":"30","author":"L Masuelli","year":"2007","unstructured":"Masuelli L, Focaccetti C, Cereda V, Lista F, Vitolo D, Trono P, Gallo P, Amici A, Monaci P, Mattei M, et al. Gene-specific inhibition of breast carcinoma in BALB-NeuT mice by active immunization with rat Neu or human ErbB receptors. Int J Oncol. 2007;30:381\u201392.","journal-title":"Int J Oncol"},{"key":"3490_CR35","first-page":"3199","volume":"47","author":"F Reale","year":"1987","unstructured":"Reale F, Griffin T, Compton J, Graham S, Townes P, Bogden A. Characterization of a Human Malignant Mesothelioma Cell Line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res. 1987;47:3199\u2013205.","journal-title":"Cancer Res"},{"key":"3490_CR36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0002-9440(10)61743-9","volume":"159","author":"A Catalano","year":"2001","unstructured":"Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol. 2001;159:721\u201331.","journal-title":"Am J Pathol"},{"key":"3490_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/019262339702500605","volume":"25","author":"L Goodglick","year":"1997","unstructured":"Goodglick L, Vaslet C, Messier N, Kane A. Growth factor responses and protooncogene expression of murine mesothelial cell lines derived from asbestos-induced mesotheliomas. Toxicol Pathol. 1997;25:565\u201373.","journal-title":"Toxicol Pathol"},{"key":"3490_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00280-007-0608-3","volume":"61","author":"C Palumbo","year":"2008","unstructured":"Palumbo C, Battisti S, Carbone D, Albonici L, Alimandi M, Bei R, Modesti A. Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed. Cancer Chemother Pharmacol. 2008;61:893\u2013901.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3490_CR39","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/nprot.2006.179","volume":"1","author":"V Vichai","year":"2006","unstructured":"Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112\u20136.","journal-title":"Nat Protoc"},{"key":"3490_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356151","volume":"6","author":"L Masuelli","year":"2017","unstructured":"Masuelli L, Granato M, Benvenuto M, Mattera R, Bernardini R, Mattei M, d\u2019Amati G, D\u2019Orazi G, Faggioni A, Bei R, et al. Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2\/Neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice. Oncoimmunology. 2017;6: e1356151.","journal-title":"Oncoimmunology"},{"key":"3490_CR41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/09637486.2016.1236077","volume":"68","author":"M Benvenuto","year":"2017","unstructured":"Benvenuto M, Mattera R, Masuelli L, Taffera G, Andracchio O, Tresoldi I, Lido P, Giganti MG, Godos J, Modesti A, et al. (\u00b1)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB\/c Mice. Int J Food Sci Nutr. 2017;68:298\u2013312.","journal-title":"Int J Food Sci Nutr"},{"key":"3490_CR42","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1007\/s13277-015-4207-3","volume":"37","author":"L Masuelli","year":"2016","unstructured":"Masuelli L, Pantanella F, La Regina G, Benvenuto M, Fantini M, Mattera R, Di Stefano E, Mattei M, Silvestri R, Schippa S, et al. Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium Lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo. Tumor Biol. 2016;37:3705\u201317.","journal-title":"Tumor Biol"},{"key":"3490_CR43","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00280-004-0838-6","volume":"54","author":"C Palumbo","year":"2004","unstructured":"Palumbo C, Albonici L, Bei R, Bocci C, Scarpa S, Di Nardo P, Modesti A. HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells. Cancer Chemother Pharmacol. 2004;54:398\u2013406.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3490_CR44","doi-asserted-by":"publisher","first-page":"10745","DOI":"10.18632\/oncotarget.2534","volume":"5","author":"L Masuelli","year":"2014","unstructured":"Masuelli L, Di Stefano E, Fantini M, Mattera R, Benvenuto M, Marzocchella L, Sacchetti P, Focaccetti C, Bernardini R, Tresoldi I, et al. Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas. Oncotarget. 2014;5:10745\u201362.","journal-title":"Oncotarget"},{"key":"3490_CR45","doi-asserted-by":"publisher","first-page":"A3.B.1","DOI":"10.1002\/0471142735.ima03bs111","volume":"111","author":"W Strober","year":"2015","unstructured":"Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 2015;111:A3.B.1.","journal-title":"Curr Protoc Immunol"},{"key":"3490_CR46","first-page":"1727","volume":"34","author":"D Alesiani","year":"2009","unstructured":"Alesiani D, Cicconi R, Mattei M, Bei R, Canini A. Inhibition of Mek 1\/2 Kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells. Int J Oncol. 2009;34:1727\u201335.","journal-title":"Int J Oncol"},{"key":"3490_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2018.01269","volume":"9","author":"M Benvenuto","year":"2018","unstructured":"Benvenuto M, Mattera R, Sticca JI, Rossi P, Cipriani C, Giganti MG, Volpi A, Modesti A, Masuelli L, Bei R. Effect of the BH3 Mimetic Polyphenol (-)-Gossypol (AT-101) on the in vitro and in vivo growth of malignant mesothelioma. Front Pharmacol. 2018;9:1\u201313.","journal-title":"Front Pharmacol"},{"key":"3490_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-015-0455-7","volume":"13","author":"M Benvenuto","year":"2015","unstructured":"Benvenuto M, Sileri P, Rossi P, Masuelli L, Fantini M, Nanni M, Franceschilli L, Sconocchia G, Lanzilli G, Arriga R, et al. Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients. J Transl Med. 2015;13:1\u201311.","journal-title":"J Transl Med"},{"key":"3490_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2017.00373","volume":"8","author":"L Masuelli","year":"2017","unstructured":"Masuelli L, Benvenuto M, Mattera R, Di Stefano E, Zago E, Taffera G, Tresoldi I, Giganti MG, Frajese GV, Berardi G, et al. In Vitro and in Vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma. Front Pharmacol. 2017;8:1\u201315.","journal-title":"Front Pharmacol"},{"key":"3490_CR50","doi-asserted-by":"publisher","first-page":"498","DOI":"10.2741\/3940","volume":"17","author":"L Masuelli","year":"2012","unstructured":"Masuelli L, Marzocchella L, Focaccetti C, Tresoldi I, Palumbo C, Izzi V, Benvenuto M, Fantini M, Lista F, Tarantino U, et al. Resveratrol and diallyl disulfide enhance curcumin-induced sarcoma cell apoptosis. Front Biosci (Landmark Ed). 2012;17:498\u2013508.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3490_CR51","doi-asserted-by":"publisher","first-page":"34405","DOI":"10.18632\/oncotarget.14907","volume":"8","author":"L Masuelli","year":"2017","unstructured":"Masuelli L, Benvenuto M, Di Stefano E, Mattera R, Fantini M, De Feudis G, De Smaele E, Tresoldi I, Giganti MG, Modesti A, et al. Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line. Oncotarget. 2017;8:34405\u201322.","journal-title":"Oncotarget"},{"key":"3490_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-98450-6","volume":"11","author":"M Benvenuto","year":"2021","unstructured":"Benvenuto M, Ciuffa S, Focaccetti C, Sbardella D, Fazi S, Scimeca M, Tundo GR, Barillari G, Segni M, Bonanno E, et al. Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells. Sci Rep. 2021;11:1\u201323.","journal-title":"Sci Rep"},{"key":"3490_CR53","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41389-019-0175-6","volume":"8","author":"E Spiombi","year":"2019","unstructured":"Spiombi E, Angrisani A, Fonte S, De Feudis G, Fabretti F, Cucchi D, Izzo M, Infante P, Miele E, Po A, et al. KCTD15 inhibits the hedgehog pathway in medulloblastoma cells by increasing protein levels of the oncosuppressor KCASH2. Oncogenesis. 2019;8:64.","journal-title":"Oncogenesis"},{"key":"3490_CR54","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/920161","volume":"2010","author":"M Podhorecka","year":"2010","unstructured":"Podhorecka M, Skladanowski A, Bozko P. H2AX Phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids. 2010;2010: 920161.","journal-title":"J Nucleic Acids"},{"key":"3490_CR55","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.molcel.2006.05.023","volume":"23","author":"C Lu","year":"2006","unstructured":"Lu C, Zhu F, Cho Y, Tang F, Zykova T, Ma W, Bode A, Dong Z. Cell Apoptosis: requirement of H2AX in DNA ladder formation, but Not for the Activation of Caspase-3. Mol Cell. 2006;23:121\u201332.","journal-title":"Mol Cell"},{"key":"3490_CR56","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2011.133","volume":"104","author":"ZI Thomas","year":"2011","unstructured":"Thomas ZI, Gibson W, Sexton JZ, Aird KM, Ingram SM, Aldrich A, Lyerly HK, Devi GR, Williams KP. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br J Cancer. 2011;104:1575\u201386.","journal-title":"Br J Cancer"},{"key":"3490_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2019.01121","volume":"10","author":"E Felley-Bosco","year":"2019","unstructured":"Felley-Bosco E. Hedgehog signaling in mesothelioma: 2019 Status. Front Genet. 2019;10:1\u20134.","journal-title":"Front Genet"},{"key":"3490_CR58","first-page":"1","volume":"3","author":"I Sullivan","year":"2016","unstructured":"Sullivan I, Planchard D. Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line. Front Med. 2016;3:1\u201313.","journal-title":"Front Med"},{"key":"3490_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102354","volume":"104","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan SH, Zhou S, Peters S, Curigliano G, Tan DSW. Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: a comparative analysis. Cancer Treat Rev. 2022;104: 102354.","journal-title":"Cancer Treat Rev"},{"key":"3490_CR60","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.2217\/fon-2020-1255","volume":"17","author":"X Mielgo-Rubio","year":"2021","unstructured":"Mielgo-Rubio X, Mart\u00edn M, Remon J, Higuera O, Calvo V, Jarabo J, Conde E, Luna J, Provencio M, De Castro J, et al. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. Futur Oncol. 2021;17:4011\u201325.","journal-title":"Futur Oncol"},{"key":"3490_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13040688","volume":"13","author":"NNN Maarof","year":"2021","unstructured":"Maarof NNN, Alsalahi A, Abdulmalek E, Fakurazi S, Tejo BA, Rahman MBA. Efficacy of afatinib in the treatment of patients with non-small cell lung cancer and head and neck squamous cell carcinoma: a systematic review and meta-analysis. Cancers (Basel). 2021;13:1\u201322.","journal-title":"Cancers (Basel)"},{"key":"3490_CR62","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3892\/ijo.2021.5168","volume":"58","author":"A Vaid","year":"2021","unstructured":"Vaid A, Gupta A, Momi G. Overall survival in Stage IV EGFR mutation-positive NSCLC: comparing first-, second- and third-generation EGFR-TKIs (Review). Int J Oncol. 2021;58:171\u201384.","journal-title":"Int J Oncol"},{"key":"3490_CR63","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2021.06.026","volume":"154","author":"F Le Du","year":"2021","unstructured":"Le Du F, Di\u00e9ras V, Curigliano G. The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. Eur J Cancer. 2021;154:175\u201389.","journal-title":"Eur J Cancer"},{"key":"3490_CR64","unstructured":"Clinical Trials.Gov Available online: www.clinicaltrials.gov. Accessed 2 May 2022."},{"key":"3490_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057346","volume":"8","author":"H Li","year":"2013","unstructured":"Li H, Lui N, Cheng T, Tseng HHK, Yue D, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, et al. Gli as a novel therapeutic target in malignant pleural mesothelioma. PLoS ONE. 2013;8: e57346.","journal-title":"PLoS ONE"},{"key":"3490_CR66","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3389\/fgene.2019.00556","volume":"10","author":"S Pietrobono","year":"2019","unstructured":"Pietrobono S, Gagliardi S, Stecca B. Non-canonical hedgehog signaling pathway in cancer: activation of GLI transcription factors beyond smoothened. Front Genet. 2019;10:556.","journal-title":"Front Genet"},{"key":"3490_CR67","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.1073\/pnas.0609699104","volume":"104","author":"M Lauth","year":"2007","unstructured":"Lauth M, Bergstr\u00f6m \u00c5, Shimokawa T, Toftg\u00e5rd R. Inhibition of GLI-Mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA. 2007;104:8455\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3490_CR68","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1002\/jcb.26572","volume":"119","author":"W Tong","year":"2018","unstructured":"Tong W, Qiu L, Qi M, Liu J, Hu K, Lin W, Huang Y, Fu J. GANT-61 and GDC-0449 induce apoptosis of prostate cancer stem cells through a GLI-dependent mechanism. J Cell Biochem. 2018;119:3641\u201352.","journal-title":"J Cell Biochem"},{"key":"3490_CR69","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jtcvs.2013.08.035","volume":"147","author":"M You","year":"2014","unstructured":"You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM. Targeting of the hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2014;147:508\u201316.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3490_CR70","doi-asserted-by":"publisher","first-page":"13899","DOI":"10.18632\/oncotarget.4224","volume":"6","author":"A Gonnissen","year":"2015","unstructured":"Gonnissen A, Isebaert S, Haustermans K. Targeting the hedgehog signaling pathway in cancer: beyond smoothened. Oncotarget. 2015;6:13899\u2013913.","journal-title":"Oncotarget"},{"key":"3490_CR71","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.3892\/or.2015.4314","volume":"34","author":"R Okita","year":"2015","unstructured":"Okita R, Uhiko Shimizu K, Nojima Y, Yukawa T, Maeda A, Saisho S, Nakata M. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells. Oncol Rep. 2015;34:2864\u201370.","journal-title":"Oncol Rep"},{"key":"3490_CR72","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.18632\/oncotarget.2729","volume":"6","author":"CB Lim","year":"2015","unstructured":"Lim CB, Pr\u00eale CM, Baltic S, Arthur PG, Creaney J, Neil Watkins D, Thompson PJ, Mutsaers SE. Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis. Oncotarget. 2015;6:1519\u201330.","journal-title":"Oncotarget"},{"key":"3490_CR73","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1177\/1947601913507951","volume":"4","author":"HK Koul","year":"2013","unstructured":"Koul HK, Pal M, Koul S. Role of P38 MAP kinase signal transduction in solid tumors. Genes Cancer. 2013;4:342\u201359.","journal-title":"Genes Cancer"},{"key":"3490_CR74","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1038\/sj.onc.1207556","volume":"23","author":"T Wada","year":"2004","unstructured":"Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004;23:2838\u201349.","journal-title":"Oncogene"},{"key":"3490_CR75","doi-asserted-by":"publisher","first-page":"8539","DOI":"10.7314\/APJCP.2014.15.20.8539","volume":"15","author":"YY Lei","year":"2014","unstructured":"Lei YY, Wang WJ, Mei JH, Wang CL. Mitogen-activated protein kinase signal transduction in solid tumors. Asian Pacific J Cancer Prev. 2014;15:8539\u201348.","journal-title":"Asian Pacific J Cancer Prev"},{"key":"3490_CR76","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/med.21574","volume":"39","author":"Q Wu","year":"2019","unstructured":"Wu Q, Wu W, Fu B, Shi L, Wang X, Kuca K. JNK signaling in cancer cell survival. Med Res Rev. 2019;39:2082\u2013104.","journal-title":"Med Res Rev"},{"key":"3490_CR77","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2013.11.019","volume":"344","author":"X Sui","year":"2014","unstructured":"Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q, He C, Pan H. P38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 2014;344:174\u20139.","journal-title":"Cancer Lett"},{"key":"3490_CR78","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1073\/pnas.0700776104","volume":"104","author":"B Stecca","year":"2007","unstructured":"Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, Beermann F, Ruiz I, Altaba A. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK\/AKT pathways. Proc Natl Acad Sci USA. 2007;104:5895\u2013900.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3490_CR79","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1073\/pnas.0504337103","volume":"103","author":"NA Riob\u00f3","year":"2006","unstructured":"Riob\u00f3 NA, Lu K, Ai X, Haines GM, Emerson CP. Phosphoinositide 3-Kinase and Akt are essential for sonic hedgehog signaling. Proc Natl Acad Sci USA. 2006;103:4505\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3490_CR80","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.CAN-05-2539","volume":"66","author":"NA Riobo","year":"2006","unstructured":"Riobo NA, Haines GM, Emerson CP. Protein kinase C-\u03b4 and mitogen-activated protein\/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signaling. Cancer Res. 2006;66:839\u201345.","journal-title":"Cancer Res"},{"key":"3490_CR81","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/0008-5472.CAN-08-2331","volume":"69","author":"H Schnidar","year":"2009","unstructured":"Schnidar H, Eberl M, Klingler S, Mangelberger D, Kasper M, Hauser-kronberger C, Regl G, Kroismayr R, Moriggl R, Sibilia M, et al. Epidermal growth factor receptor signaling synergizes with Hedgehog\/GLI in oncogenic transformation via activation of the ME\/ERK\/JUN pathway. Cancer Res. 2009;69:1284\u201392.","journal-title":"Cancer Res"},{"key":"3490_CR82","doi-asserted-by":"publisher","first-page":"23020","DOI":"10.18632\/oncotarget.15479","volume":"8","author":"CM Della Corte","year":"2017","unstructured":"Della Corte CM, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, et al. Efficacy of continuous EGFR-inhibition and role of hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. Oncotarget. 2017;8:23020\u201332.","journal-title":"Oncotarget"},{"key":"3490_CR83","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jtho.2016.01.014","volume":"11","author":"WA Buikhuisen","year":"2016","unstructured":"Buikhuisen WA, Scharpfenecker M, Griffioen AW, Korse CM, Van Tinteren H, Baas P. A Randomized Phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes. J Thorac Oncol. 2016;11:758\u201368.","journal-title":"J Thorac Oncol"},{"key":"3490_CR84","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","volume":"8","author":"S Papa","year":"2013","unstructured":"Papa S, Popat S, Shah R, Prevost AT, Lal R, McLennan B, Cane P, Lang-Lazdunski L, Viney Z, Dunn JT, et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol. 2013;8:783\u20137.","journal-title":"J Thorac Oncol"},{"key":"3490_CR85","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","volume":"5","author":"S Dubey","year":"2010","unstructured":"Dubey S, J\u00e4nne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, et al. A Phase II study of sorafenib in malignant mesothelioma: results of cancer and leukemia Group B 30307. J Thorac Oncol. 2010;5:1655\u201361.","journal-title":"J Thorac Oncol"},{"key":"3490_CR86","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cllc.2013.12.008","volume":"15","author":"AS Tsao","year":"2014","unstructured":"Tsao AS, Harun N, Lee J, Heymach J, Pisters K, Hong W, Fujimoto J, Wistuba I. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014;15:197\u2013201.","journal-title":"Clin Lung Cancer"},{"key":"3490_CR87","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1200\/JCO.19.00269","volume":"37","author":"AS Tsao","year":"2019","unstructured":"Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-na\u00efve patients with unresectable malignant pleural mesothelioma (SWOG S0905). J Clin Oncol. 2019;37:2537\u201347.","journal-title":"J Clin Oncol"},{"key":"3490_CR88","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/0008-5472.CAN-19-1633","volume":"80","author":"M Marques","year":"2020","unstructured":"Marques M, Tranchant R, Risa-Ebr\u00ed B, Suarez-Sol\u00eds ML, Fernandez LC, Carrillo-De-Santa-Pau E, Del Pozo N, De Villarreal JM, Meiller C, Allory Y, et al. Combined MEK and PI3K\/P110\u03b2 inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features. Cancer Res. 2020;80:843\u201356.","journal-title":"Cancer Res"},{"key":"3490_CR89","doi-asserted-by":"publisher","first-page":"5817","DOI":"10.3390\/ijms20225817","volume":"20","author":"A Belfiore","year":"2019","unstructured":"Belfiore A, Busico A, Bozzi F, Brich S, Dallera E, Conca E, Capone I, Gloghini A, Volpi CC, Cabras AD, et al. Molecular signatures for combined targeted treatments in diffuse malignant peritoneal mesothelioma. Int J Mol Sci. 2019;20:5817.","journal-title":"Int J Mol Sci"},{"key":"3490_CR90","first-page":"138","volume":"22","author":"PA Prieto","year":"2016","unstructured":"Prieto PA, Reuben A, Cooper ZA, Wargo JA. Targeted therapies combined with immune checkpoint therapy. Cancer J (United States). 2016;22:138\u201346.","journal-title":"Cancer J (United States)"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03490-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T13:21:44Z","timestamp":1675948904000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03490-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3490"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03490-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}